1. Home
  2. FEBO vs BNGO Comparison

FEBO vs BNGO Comparison

Compare FEBO & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

HOLD

Current Price

$1.17

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.10

Market Cap

11.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
BNGO
Founded
1993
2003
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.6M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
FEBO
BNGO
Price
$1.17
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.33
AVG Volume (30 Days)
9.1K
88.7K
Earning Date
04-24-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000,735.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$24.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.26
52 Week Low
$0.61
$1.06
52 Week High
$1.48
$5.50

Technical Indicators

Market Signals
Indicator
FEBO
BNGO
Relative Strength Index (RSI) 55.38 40.45
Support Level $1.04 $1.07
Resistance Level $1.19 $1.18
Average True Range (ATR) 0.05 0.04
MACD 0.02 0.01
Stochastic Oscillator 68.42 40.00

Price Performance

Historical Comparison
FEBO
BNGO

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Share on Social Networks: